Could you share recent papers on dual antiplatelet therapy (aspirin and clopidogrel) for atherosclerotic basilar artery disease?

Dual Antiplatelet Therapy for Atherosclerotic Basilar Artery Disease

Primary Recommendation

For patients with symptomatic atherosclerotic basilar artery stenosis presenting with minor stroke (NIHSS ≤3) or high-risk TIA within 24 hours, initiate dual antiplatelet therapy with aspirin plus clopidogrel for exactly 21 days, then transition to single antiplatelet therapy indefinitely. 1, 2

---

Patient Selection Criteria

Eligible for Short-Term DAPT (21 Days)

• Minor ischemic stroke in basilar territory with NIHSS ≤3 presenting within 24 hours of symptom onset 1
• High-risk TIA (ABCD² score ≥4) in basilar distribution presenting within 24 hours 1
• Intracranial hemorrhage must be excluded on urgent CT or MRI before any antiplatelet agent is administered 1
• No recent thrombolysis (if IV alteplase given, wait ≥24 hours and obtain repeat imaging) 1

Ineligible for DAPT – Use Aspirin Monotherapy Instead

• Moderate-to-severe stroke (NIHSS >3) in basilar territory 1
• Presentation >72 hours after symptom onset 1
• Active major bleeding, severe thrombocytopenia, or known aspirin/clopidogrel allergy 1
• Cardioembolic source identified (requires anticoagulation, not antiplatelet therapy) 1

---

DAPT Protocol for Eligible Patients

Loading Dose (Day 1)

• Clopidogrel 300 mg (acceptable range 300-600 mg; the 300 mg dose from CHANCE trial carries modestly lower bleeding risk) 1
• Aspirin 160-325 mg (avoid enteric-coated formulations for loading dose) 1
• Administer within 12-24 hours of symptom onset for maximal efficacy 1

Maintenance Phase (Days 2-21)

• Clopidogrel 75 mg once daily 1
• Aspirin 75-100 mg once daily 1
• Continue for exactly 21 days total from the index event 1

Transition to Long-Term Therapy (Day 22 Onward)

• Discontinue one agent and continue single antiplatelet therapy indefinitely: 1
  • First-line: Aspirin 75-100 mg daily 1
  • Alternative: Clopidogrel 75 mg daily (preferred in patients with diabetes, aspirin intolerance, or peripheral arterial disease) 1, 3
  • Another option: Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily 1

---

Evidence Supporting DAPT in Basilar Artery Disease

Efficacy Data

• A randomized trial of 574 patients with large artery atherosclerosis stroke (including basilar artery) demonstrated that clopidogrel plus aspirin reduced early neurological deterioration and recurrent ischemic stroke within 30 days compared to aspirin alone 2
• At 6 months, dual therapy improved outcomes specifically in patients with symptomatic stenosis in the posterior circulation and basilar artery 2
• Meta-analysis of 21,459 patients showed DAPT reduces recurrent stroke by 24% (RR 0.76,95% CI 0.68-0.83) compared to aspirin alone 4

Safety Profile

• Major bleeding increases with DAPT (RR 2.22,95% CI 1.14-4.34), occurring in approximately 0.9% versus 0.4% with aspirin alone 4
• The number needed to treat to prevent one recurrent stroke is 67-91, while the number needed to harm with major bleeding is approximately 200 1
• Extending DAPT beyond 21-30 days markedly increases bleeding risk (RR 2.42,95% CI 1.37-4.30) without additional stroke prevention benefit 1, 4

---

Critical Contraindications & Pitfalls

Absolute Contraindications

• Do NOT use DAPT as a substitute for thrombolysis or mechanical thrombectomy in patients eligible for those definitive reperfusion therapies 1
• Do NOT initiate DAPT if intracranial hemorrhage has not been ruled out on neuroimaging 1
• Do NOT use DAPT in patients with NIHSS >3 (use aspirin monotherapy instead) 1

Common Pitfalls to Avoid

• Do NOT extend DAPT beyond 21-30 days unless a separate cardiac indication exists (e.g., recent coronary stent), as bleeding risk outweighs benefit 1, 4
• Do NOT delay DAPT initiation beyond 24 hours when eligibility criteria are met; maximal efficacy occurs within the first 12-24 hours 1
• Do NOT use ticagrelor instead of clopidogrel for acute minor stroke in basilar territory; it carries higher bleeding risk without proven superiority 1
• Do NOT use glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) in acute ischemic stroke; they are potentially harmful 1

---

Special Populations & Practical Considerations

Patients with Dysphagia or Impaired Swallowing

• Deliver clopidogrel 75 mg + aspirin 81 mg via enteral feeding tube, or use aspirin 325 mg rectal suppository as an alternative 1

Patients with Severe Renal Impairment (CrCl <30 mL/min)

• Use aspirin monotherapy only (loading 160-325 mg, then 75-100 mg daily); clopidogrel is contraindicated due to metabolite accumulation and heightened bleeding risk 1

Elderly Patients (≥70 Years)

• No excess bleeding risk was observed with DAPT in patients ≥70 years in the COMMIT trial, supporting use of the standard regimen 1

---

Long-Term Management Beyond Antiplatelet Therapy

• Initiate high-intensity statin therapy (e.g., atorvastatin 80 mg daily) targeting LDL <70 mg/dL 1
• Control blood pressure to <140/90 mmHg, with individualized targets for patients with severe stenosis 1
• Optimize diabetes management when present 1
• Address modifiable vascular risk factors aggressively, as basilar artery disease carries markedly higher rates of poor functional outcome and stroke recurrence 1

---

Evidence Quality Summary

• The 21-day DAPT regimen is supported by Class I, Level A evidence from large randomized controlled trials (CHANCE, POINT) with pooled analysis of >10,000 patients 1
• Specific evidence for basilar artery stenosis comes from a randomized trial of 574 patients demonstrating superiority of DAPT over aspirin alone for reducing early neurological deterioration and improving 6-month outcomes in posterior circulation disease 2
• The recommendation against extending DAPT beyond 21-30 days is supported by high-quality meta-analysis showing increased bleeding without additional benefit 4